Pfizer Gross Profit 2010-2022 | PFE

Pfizer annual/quarterly gross profit history and growth rate from 2010 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • Pfizer gross profit for the quarter ending December 31, 2022 was $14.642B, a 3.83% increase year-over-year.
  • Pfizer gross profit for the twelve months ending December 31, 2022 was $65.988B, a 30.75% increase year-over-year.
  • Pfizer annual gross profit for 2022 was $65.986B, a 30.75% increase from 2021.
  • Pfizer annual gross profit for 2021 was $50.467B, a 52.16% increase from 2020.
  • Pfizer annual gross profit for 2020 was $33.167B, a 0.96% increase from 2019.
Pfizer Annual Gross Profit
(Millions of US $)
2022 $65,986
2021 $50,467
2020 $33,167
2019 $32,851
2018 $31,838
2017 $41,318
2016 $40,502
2015 $39,203
2014 $40,028
2013 $41,998
2012 $44,836
2011 $48,535
2010 $50,377
2009 $40,810
Pfizer Quarterly Gross Profit
(Millions of US $)
2022-12-31 $14,642
2022-09-30 $16,575
2022-06-30 $19,094
2022-03-31 $15,677
2021-12-31 $14,102
2021-09-30 $14,103
2021-06-30 $11,903
2021-03-31 $10,359
2020-12-31 $8,716
2020-09-30 $8,270
2020-06-30 $8,038
2020-03-31 $8,143
2019-12-31 $1,400
2019-09-30 $10,078
2019-06-30 $10,688
2019-03-31 $10,685
2018-12-31 $341
2018-09-30 $10,604
2018-06-30 $10,550
2018-03-31 $10,343
2017-12-31 $10,447
2017-09-30 $10,324
2017-06-30 $10,236
2017-03-31 $10,311
2016-12-31 $10,415
2016-09-30 $9,960
2016-06-30 $9,973
2016-03-31 $10,154
2015-12-31 $10,636
2015-09-30 $9,868
2015-06-30 $9,673
2015-03-31 $9,026
2014-12-31 $10,416
2014-09-30 $9,993
2014-06-30 $10,311
2014-03-31 $9,308
2013-12-31 $10,764
2013-09-30 $10,356
2013-06-30 $10,731
2013-03-31 $10,147
2012-12-31 $10,460
2012-09-30 $10,644
2012-06-30 $11,592
2012-03-31 $12,140
2011-12-31 $9,612
2011-09-30 $13,200
2011-06-30 $12,914
2011-03-31 $12,809
2010-12-31 $12,350
2010-09-30 $12,205
2010-06-30 $13,448
2010-03-31 $12,374
2009-12-31 $12,291
2009-09-30 $9,832
2009-06-30 $9,228
2009-03-31 $9,459
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $248.894B $100.330B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $432.802B 16.29
Eli Lilly (LLY) United States $314.224B 41.65
Novo Nordisk (NVO) Denmark $299.481B 38.14
Merck (MRK) United States $262.312B 13.83
AbbVie (ABBV) United States $256.147B 10.62
Novartis AG (NVS) Switzerland $190.505B 14.09